7-Azaindole derivatives as potential partial nicotinic agonists
摘要:
We have investigated a series of 7-azaindoles as potential partial agonists of the alpha 4 beta 2 nicotinic acetylcholine receptor (nAChR). Three series of 7-azaindole derivatives have been synthesized and evaluated for rat brain neuronal nicotinic receptor affinity and functional activity. Compound (+)-51 exhibited the most potent nAChR binding (K-i = 10 nM). Compound 30A demonstrated both moderate binding affinity and partial agonist potency, thus representing a promising lead for the indications of cognition and smoking cessation. (C) 2007 Elsevier Ltd. All rights reserved.
7-Azaindole derivatives as potential partial nicotinic agonists
摘要:
We have investigated a series of 7-azaindoles as potential partial agonists of the alpha 4 beta 2 nicotinic acetylcholine receptor (nAChR). Three series of 7-azaindole derivatives have been synthesized and evaluated for rat brain neuronal nicotinic receptor affinity and functional activity. Compound (+)-51 exhibited the most potent nAChR binding (K-i = 10 nM). Compound 30A demonstrated both moderate binding affinity and partial agonist potency, thus representing a promising lead for the indications of cognition and smoking cessation. (C) 2007 Elsevier Ltd. All rights reserved.
7-Azaindole derivatives as potential partial nicotinic agonists
作者:Axel R. Stoit、Arnold P. den Hartog、Harry Mons、Sjoerd van Schaik、Nynke Barkhuijsen、Cees Stroomer、Hein K.A.C. Coolen、Jan Hendrik Reinders、Tiny J.P. Adolfs、Martina van der Neut、Hiskias Keizer、Chris G. Kruse
DOI:10.1016/j.bmcl.2007.10.101
日期:2008.1
We have investigated a series of 7-azaindoles as potential partial agonists of the alpha 4 beta 2 nicotinic acetylcholine receptor (nAChR). Three series of 7-azaindole derivatives have been synthesized and evaluated for rat brain neuronal nicotinic receptor affinity and functional activity. Compound (+)-51 exhibited the most potent nAChR binding (K-i = 10 nM). Compound 30A demonstrated both moderate binding affinity and partial agonist potency, thus representing a promising lead for the indications of cognition and smoking cessation. (C) 2007 Elsevier Ltd. All rights reserved.